SCHEMBL5457564

SCHEMBL5457564

O=C(O)C=Cc1ccc(-c2ccsc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.52
HCAR2 Q8TDS4 2/20 0.52
CA12 O43570 2/20 0.52
AKR1B10 O60218 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA3 P07451 2/20 0.52
AKR1B1 P15121 2/20 0.52
CA4 P22748 2/20 0.52
CA6 P23280 2/20 0.52
DPP4 P27487 2/20 0.52
CA5A P35218 2/20 0.52
CA7 P43166 2/20 0.52
CA9 Q16790 2/20 0.52
CA14 Q9ULX7 2/20 0.52
CA5B Q9Y2D0 2/20 0.52
PKM P14618 1/20 0.52
TYR P14679 1/20 0.52
ESR2 Q92731 1/20 0.52
HDAC2 Q92769 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4946176 0.83 HCAR2 (0.71) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL4946181 0.83 HCAR2 (0.71) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL9254826 0.81 NPSR1 (0.51) HCAR2CA12AKR1B10CA1CA2
SCHEMBL9254831 0.81 NPSR1 (0.51) HCAR2CA12AKR1B10CA1CA2
SCHEMBL12924107 0.80 HCAR2 (0.54) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL1126746 0.80 HCAR2 (0.54) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL1126747 0.80 HCAR2 (0.54) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL165794 0.77 HDAC2 (0.75) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL165795 0.77 HDAC2 (0.75) ESR1HCAR2CA12AKR1B10CA1
SCHEMBL9254956 0.77 HCAR2 (0.49) HCAR2HDAC2HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294636-B2 Chemical compounds ASTRAZENECA AB (SE) 2007-11-13 US disclosed
US-20070015788-A1 N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis ASTRAZENECA AB (SE) 2007-01-18 US disclosed
EP-1625120-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2006-02-15 EP disclosed
WO-2004099178-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015788-A1 N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis CCR5, CCR2, CX3CR1 ESR1 1905/4885HCAR2 93/4885CA12 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.